Aaron M. Etra

Hematology | Oncology
1470 Madison Ave Fl 3
New York, NY 10029

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.

Journal: medRxiv : the preprint server for health sciences
Published: July 29, 2026

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Journal: Blood immunology & cellular therapy
Published: May 15, 2026

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.

Journal: Transplantation and cellular therapy
Published: July 31, 2025

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.

Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.

Journal: Blood
Published: July 09, 2025

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.

Journal: Blood advances
Published: May 09, 2025

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.

Journal: Blood advances
Published: February 14, 2025

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.

Journal: Transplantation and cellular therapy
Published: September 09, 2024

Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.

Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.

Journal: Gut
Published: August 08, 2024

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

Journal: Blood advances
Published: July 29, 2024

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.

Journal: Transplantation and cellular therapy
Published: June 26, 2024

The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.

The reparative immunologic consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.

Journal: bioRxiv : the preprint server for biology
Published: June 19, 2024

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.

Journal: Blood
Published: April 26, 2024
Showing 1-12 of 33

Last Updated: 09/26/2026